Igor Samatoshenkov | Medicine | Best Researcher Award

Mr. Igor Samatoshenkov | Medicine | Best Researcher Award

Vascular surgeon, Uniclinic Brandenburg, Medical school Brandenburg, Germany

Dr. Samatoshenkov Igor Valeryevich  is an accomplished cardiovascular surgeon, innovator, and medical entrepreneur, currently based in Brandenburg, Germany. With an MD and PhD in medical sciences, he has made significant strides in the fields of vascular surgery, regenerative medicine, and gene therapy. He is the founder and CEO of “Angiolife,” a Skolkovo-based biotech company pioneering gene-drug research. As a dedicated academic and clinical expert, Dr. Samatoshenkov has been actively involved in cutting-edge surgical practice, scientific research, and medical education. 🧬💉

Publication Profile

Scopus

ORCID

🎓 Education Background

Dr. Samatoshenkov earned his PhD in 2021 from Kazan Federal University 🎓. His earlier training includes a medical degree from Kazan State Medical University (2009–2015), where he also specialized as a professional medical translator (2012–2014). He pursued advanced phlebology training in endovenous laser obliteration in 2018 in Moscow. His comprehensive education has built a solid foundation for his clinical and research pursuits. 📚🩺

💼 Professional Experience

Dr. Samatoshenkov has over a decade of experience in cardiovascular surgery and medical education. Since 2017, he has been serving in the Department of Cardiosurgery No. 1 and is a graduate student in the Department of Histology, Cytology, and Embryology. From 2015 to 2017, he was an attending physician in the Department of Heart Surgery at the ICDC. He also contributed to academia as an assistant in the Department of Normal Anatomy (2016–2017) and led several student scientific circles from 2011 to 2014. In 2018, he founded “Angiolife,” advancing gene-based therapeutics. 🏥💡

🏆 Awards and Honors

Dr. Samatoshenkov’s innovations have been widely recognized. He won the 2023 National Competition of Innovative Ideas in Medicine by AMTEC Foundation 🏅 and the “Top 50 Innovative Ideas” contest in Tatarstan 🥇. He was a finalist in the 2022 MEDLEADS competition and ranked 2nd in the 2021 All-Russian Intellectual Property contest “Intellect.” He also received accolades from the Academy of Sciences of Tatarstan (2020) and Innopolis Startup Tour (3rd place). 🌟🔬

🔬 Research Focus

Dr. Samatoshenkov’s research spans cardiovascular regeneration, gene and stem cell therapy, and surgical innovation. His pioneering studies in VEGF, ANG, and GDNF gene delivery have opened promising avenues in post-ischemic tissue recovery. His experimental models and cell-mediated delivery techniques are pushing the boundaries of modern medicine. 🧪🧠

🔚 Conclusion

With an exceptional blend of clinical excellence, scientific ingenuity, and entrepreneurial vision, Dr. Igor Samatoshenkov is a leading figure in cardiovascular innovation and regenerative therapy. His mission continues to bridge advanced research with real-world patient solutions. 🌐

📘 Top Publications

  1. Modeling of acute venous lesion of the lower extremities in experiment (2016) – Clinical and Experimental Surgery
    Authors: I.V. Samatoshenkov, B.M. Mirolyubov
    Cited by: —
    Journal Link: Not publicly available online

  2. Effects of direct and indirect delivery of the VEGF gene by cord blood cells to the area of limb ischemia in rats (2017) – Morphological Statements
    Authors: I.V. Samatoshenkov, S.A. Andreev, N.V. Boychuk
    🔗 https://doi.org/10.20340/mv-mn.2017(25).4.14-17
    Cited by: 5+

  3. Comparison of the effectiveness of stimulating angiogenesis in ischemic limbs… (2019) – Creative Cardiology
    Authors: I.V. Samatoshenkov et al.
    🔗 https://doi.org/10.24022/1997-3187-2019-13-3-250-262
    Cited by: 10+

  4. Stimulation of angiogenesis of rat skeletal muscle… (2020) – Morphology
    🔗 https://doi.org/10.34922/AE.2020.157.1.006
    Cited by: 15+

  5. Adenoviral vector delivery of VEGF, angiogenin, and GDNF genes promotes angiogenesis… (2020) – BioNanoScience
    Authors: I.V. Samatoshenkov et al.
    🔗 https://doi.org/10.1007/s12668-019-00688-y
    Cited by: 25+

  6. New experimental model of hind limb ischemia in pot-bellied pigs (2023) – Microvascular Research
    Authors: Igor Samatoshenkov et al.
    🔗 https://doi.org/10.1016/j.mvr.2022.104425
    Cited by: 8+

  7. Combined delivery of the VEGF, ANG, and GDNF genes stimulates angiogenesis and post-ischemic regeneration (2024) – Current Issues in Molecular Biology
    🔗 https://doi.org/10.3390/cimb46080507
    Cited by: 12+

 

Ms. tianyu zhou | Health Sciences | Best Researcher Award

Ms. tianyu zhou | Health Sciences | Best Researcher Award

Editor, Disease Control And Prevetion, China

Zhou Tianyu is a dedicated researcher in the field of pharmacology, specializing in drug safety evaluation and molecular pharmacology. Born in Weinan City, Shaanxi Province, China, she has an extensive background in pharmacy and biomedical research. With a strong passion for scientific exploration, she has actively contributed to multiple national research projects, focusing on drug mechanisms, adverse drug reactions, and bioinformatics analysis. Her research expertise includes PCR, Western blot, flow cytometry, and serum pharmacology, making her proficient in both experimental operations and data analysis.

Publication Profile

Scopus

🎓 Education

Zhou Tianyu earned her Master’s degree in Pharmacy from Shaanxi University of Chinese Medicine (2021-2024), where she studied advanced courses such as Pharmacology, Medicinal Chemistry, and Molecular Biology. She also completed her undergraduate studies at the same institution (2017-2021), gaining in-depth knowledge of Organic Chemistry, Analytical Chemistry, and Natural Drug Chemistry. Her academic journey has equipped her with strong theoretical and practical skills in pharmaceutical sciences.

🏆 Experience

Throughout her research career, Zhou Tianyu has been involved in numerous prestigious projects. She contributed to the study of donkey-hide gelatin’s role in regulating alveolar macrophage transformation in chronic obstructive pulmonary disease (COPD) based on the TLR/NF-κB/L-arginine signaling axis. She successfully built a COPD mouse model and conducted inflammation studies using RAW264.7 cells. Additionally, she worked on mining adverse drug reactions from the FAERS database, leading to a published article in Scientific Reports. Her industrial experience includes internships at Xi’an Zhengda Pharmaceutical Co., Ltd. and Beijing Union Jianhao Pharmaceutical Technology Development Co., Ltd., where she specialized in drug processing, safety evaluation, and archives management.

🏅 Awards and Honors

Zhou Tianyu’s academic excellence has been recognized with the Third-Class Postgraduate Scholarship (2022). She has also actively participated in social service and professional activities, earning the title of “Excellent Volunteer” in the “Serving the Society, Caring for Health” Free Clinic (2017-2018) and at the 13th Shaanxi Province Games (2018). Furthermore, she secured third place in the “Shennong Painting Hundreds of Herbs—Chinese Medicine Painting Exhibition” and held leadership roles in her university’s Youth League Organization.

🔍 Research Focus

Her research interests include drug safety evaluation, bioinformatics, network pharmacology, and molecular mechanisms of drug action. She has contributed significantly to studying the anti-pulmonary fibrosis effects of Prismatomeris connata extract using spatially resolved metabolomics. She also explored hepatotoxicity mechanisms in Polygonum multiflorum through network toxicology. Her expertise extends to allergy research, where she investigated inflammatory mediator responses in RBL2H3 cells.

📝 Conclusion

Zhou Tianyu is an ambitious and skilled researcher with a strong foundation in pharmacology, data analysis, and experimental methodologies. Her ability to integrate bioinformatics with laboratory research has contributed to high-impact publications and drug safety assessments. With her keen analytical mind and collaborative nature, she continues to explore innovative pharmaceutical solutions while striving for excellence in drug research and evaluation.

📚 Publications

Spatially resolved metabolomics visualizes heterogeneous distribution of metabolites in lung tissue and the anti-pulmonary fibrosis effect of Prismatomeris connata extract

Unraveling the mechanism of ethyl acetate extract from Prismatomeris connata Y. Z. Ruan root in treating pulmonary fibrosis: insights from bioinformatics, network pharmacology, and experimental validation

 Inegrated spatially resolved metabolomics and network toxicology to investigate the hepatotoxicity mechanisms of component D of Polygonum multiflorum Thunb.